Anna Berkenblit M.D., MM.Sc — Chief Medical Officer and Vice President at ImmunoGen

Dr. Anna Berkenblit, M.D., MM.Sc, has been Chief Medical Officer and Vice President of ImmunoGen, Inc. since April 01, 2015. Dr. Berkenblit served as Head of Clinical Research and Vice President at AVEO Pharmaceuticals, Inc. (AVEO Oncology). She joined AVEO in 2011 and has six years experience in the industry. She was previously with Wyeth Research, where she joined the Torisel (temsirolimus, CCI-779) team and ultimately led the clinical development and global approval of Torisel for renal cell cancer, as well as the European approval of Torisel for mantle cell lymphoma. She led clinical efforts in lifecycle planning and ran the compassionate use program for Torisel prior to moving to the Neratinib (HKI-272) program as the lead U.S. physician on the clinical team. She served as Senior Vice President of Clinical Development at H3 Biomedicine Inc. After the acquisition of Wyeth by Pfizer, Dr. Berkenblit became the Vice President and asset team leader for Neratinib, accountable for driving the development, implementation and delivery of the integrated asset plan strategy. Prior to her career in industry, she ran the Phase 1 oncology clinical trial program at the Beth Israel Deaconess Medical Center in Boston, MA, as part of the Dana-Farber/Harvard Cancer Center. She received her postgraduate training in internal medicine/primary care at Brigham and Women's Hospital/Harvard Vanguard Medical Associates, followed by subspeciality training in hematology/medical oncology at Beth Israel Deaconess Medical Center, where she also earned a master's degree in medical science through Harvard University and Massachusetts Institute of Technology. She holds MMSc degree in the Clinical Investigator Training Program of Harvard/MIT Health Sciences & Technology. Dr. Berkenblit received her B.S. from Yale College and her M.D. from Harvard Medical School.